ESPE Abstracts

Background: Traditionally patients with X-linked Hypophosphatemic Rickets (XLH) have been treated with conventional therapy, however, in 2018, the FDA approved Burosumab use in XLH patients.Objective: To investigate Burosumab effectiveness on pediatric patients with XLH by observing an improvement in serum phosphorus concentration and total rickets severity score (RSS) within 12 months period.<stro...